| Version |
2.5 |
| Creation Date |
2005-06-13 13:24:05 |
| Update Date |
2009-02-19 16:04:57 |
| Primary Accession Number |
DB00780 |
| Secondary Accession Number |
|
| Name |
Phenelzine |
| Drug Type |
|
| Description |
One of the monoamine oxidase inhibitors used to treat depression; phobic disorders; and panic. [PubChem] |
| Synonyms |
Not Available |
| Brand Names |
- Beta-phenylethylhydrazine
- Fenelzina [INN-Spanish]
- Fenelzyna
- Fenelzyne
- Nardil
- Phenalzine
- Phenelezine
- Phenelzinum [INN-Latin]
- Phenethylhydrazine
- Phenylethyl hydrazine-HCl
- Phenylethylhydrazine
- Stinerval
|
| Brand Mixtures |
Not Available |
| Chemical IUPAC Name |
2-phenylethylhydrazine |
| Chemical Formula |
C8H12N2 |
| Chemical Structure |
 |
| CAS Registry Number |
51-71-8 |
| InChI Identifier |
InChI=1/C8H12N2/c9-10-7-6-8-4-2-1-3-5-8/h1-5,10H,6-7,9H2 |
| InChI Key |
RMUCZJUITONUFY-UHFFFAOYAD |
| KEGG Drug |
Not Available |
| KEGG Compound |
C07430  |
| PubChem Compound |
3675  |
| PubChem Substance |
9634  |
| ChEBI ID |
Not Available |
| PharmGKB ID |
PA450903  |
| HET ID |
Not Available |
| GenBank ID |
Not Available |
| Drug ID Number [DIN] |
00476552  |
| RxList Link |
http://www.rxlist.com/cgi/generic2/phenelzine.htm  |
| PDRhealth Link |
Not Available |
| Wikipedia Link |
http://en.wikipedia.org/wiki/Phenelzine  |
| FDA Label |
|
| Material Safety Data Sheet (MSDS) |
Not Available |
| Synthesis Reference |
Votocek, Leminger, Coll. Czech. Chem. Commun. 4, 271 (1932), C.A. 26, 5294 (1932) |
| Average Molecular Weight |
136.1943 |
| Monoisotopic Molecular Weight |
136.1000 |
| State |
Liquid |
| Melting Point |
< 25 oC |
| Experimental Water Solubility |
29.1 g/L
Source: PhysProp
|
| Predicted Water Solubility |
1.11e+01 mg/mL
Calculated using ALOGPS
|
| Experimental LogP/Hydrophobicity |
1.1
Source: PhysProp
|
| Predicted LogP |
1.20
Calculated using ALOGPS
|
| Experimental LogS |
Not Available |
| Predicted LogS |
-1.09
Calculated using ALOGPS
|
| Experimental Caco2 Permeability |
Not Available |
| pKa/Isoelectric Point |
Not Available |
| Mass Spectrum |
Not Available
|
| MOL File |
Show | Download  |
| SDF File |
Show | Download  |
| PDB File |
Show | Download  |
| 2D Structure |
|
| 3D Structure |
|
| Experimental PDB ID |
1O5W  |
| Experimental PDB File |
Show |
| Experimental PDB Structure |
|
| Isomeric SMILES |
NNCCC1=CC=CC=C1 |
| Canonical SMILES |
NNCCC1=CC=CC=C1 |
| Drug Category |
- Antidepressants
- Antidepressive Agents
- Monoamine Oxidase Inhibitors
|
| ATC Codes |
|
| AHFS Codes |
|
| Indication |
For the treatment of depression. |
| Pharmacology |
Phenelzine belongs to a class of antidepressants called monoamine oxidase inhibitors (MAOIs). Phenelzine works by irreversibly blocking the action of a chemical substance known as monoamine oxidase (MAO) in the nervous system. Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. |
| Mechanism of Action |
The irreversible inhibition of MAO by phenelzine causes an increase in the levels of serotonin, norepinephrine, and dopamine in the neuron, relieving depressive symptoms. |
| Absorption |
Readily absorbed after oral administration. |
| Toxicity |
Symptoms of overdose include drowsiness, dizziness, faintness, irritability, hyperactivity, agitation, severe headache, hallucinations, trismus, opisthotonos, convulsions and coma, rapid and irregular pulse, hypertension, hypotension and vascular collapse, precordial pain, respiratory depression and failure, hyperpyrexia, diaphoresis, and cool, clammy skin. |
| Protein Binding |
Not Available |
| Biotransformation |
Hepatic. Acetylation of phenelzine appears to be a minor metabolic pathway. Beta-phenylethylamine is a metabolite of phenelzine, and there is indirect evidence that phenelzine may also be ring-hydroxylated and N-methylated. |
| Half Life |
Not Available |
| Dosage Forms |
|
| Patient Information |
Show  |
| Contraindications |
Show  |
| Interactions |
Show  |
| Drug Interactions |
| Drug |
Interaction |
| Acetohexamide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Almotriptan |
The MAO inhibitor increases the effect and toxicity of 5-HT agonist |
| Altretamine |
Risk of severe hypotension |
| Amitriptyline |
Possibility of severe adverse effects |
| Amoxapine |
Possibility of severe adverse effects |
| Amphetamine |
Possible hypertensive crisis |
| Atomoxetine |
Possible severe adverse reaction with this combination |
| Benzphetamine |
Possible hypertensive crisis |
| Bupropion |
Possible severe adverse reaction with this combination |
| Buspirone |
Possible blood pressure elevation |
| Chlorpropamide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Citalopram |
Possible severe adverse reaction with this combination |
| Clomipramine |
Possibility of severe adverse effects |
| Desipramine |
Possibility of severe adverse effects |
| Dexfenfluramine |
Possible hypertensive crisis |
| Dextroamphetamine |
Possible hypertensive crisis |
| Dextromethorphan |
Possible severe adverse reaction |
| Diethylpropion |
Possible hypertensive crisis |
| Dobutamine |
Increased arterial pressure |
| Donepezil |
Possible antagonism of action |
| Dopamine |
Increased arterial pressure |
| Doxepin |
Possibility of severe adverse effects |
| Duloxetine |
Possible severe adverse reaction with this combination |
| Entacapone |
Possible hypertensive crisis with this combination |
| Ephedra |
Increased arterial pressure |
| Ephedrine |
Increased arterial pressure |
| Epinephrine |
Increased arterial pressure |
| Escitalopram |
Possible severe adverse reaction with this combination |
| Fenfluramine |
Possible hypertensive crisis |
| Fenoterol |
Increased arterial pressure |
| Fluoxetine |
Possible severe adverse reaction with this combination |
| Fluvoxamine |
Possible severe adverse reaction with this combination |
| Galantamine |
Possible antagonism of action |
| Ginseng |
Ginseng increases the effect and toxicity of MAOI |
| Glibenclamide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Gliclazide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Glipizide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Glisoxepide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Glycodiazine |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Guanethidine |
The agent decreases the effect of guanethidine |
| Imipramine |
Possibility of severe adverse effects |
| Insulin |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Isoproterenol |
Increased arterial pressure |
| Levodopa |
Possible hypertensive crisis |
| Mazindol |
Possible hypertensive crisis |
| Meperidine |
Potentially fatal adverse effects |
| Mephentermine |
Increased arterial pressure |
| Metaraminol |
Increased arterial pressure |
| Methamphetamine |
Possible hypertensive crisis |
| Methotrimeprazine |
Possible severe adverse reaction with this combination |
| Methoxamine |
Increased arterial pressure |
| Methylphenidate |
Possible hypertensive crisis with this combination |
| Midodrine |
Possible hypertensive crisis with this combination |
| Mirtazapine |
Possible severe adverse reaction with this combination |
| Naratriptan |
The MAO inhibitor increases the effect and toxicity of 5-HT agonist |
| Nefazodone |
Possible severe adverse reaction with this combination |
| Norepinephrine |
Increased arterial pressure |
| Nortriptyline |
Possibility of severe adverse effects |
| Orciprenaline |
Increased arterial pressure |
| Paroxetine |
Possible severe adverse reaction with this combination |
| Phendimetrazine |
Possible hypertensive crisis |
| Phendimetrazine |
Possible hypertensive crisis |
| Phentermine |
Possible hypertensive crisis |
| Phenylephrine |
Increased arterial pressure |
| Phenylpropanolamine |
Increased arterial pressure |
| Pirbuterol |
Increased arterial pressure |
| Procaterol |
Increased arterial pressure |
| Protriptyline |
Possibility of severe adverse effects |
| Pseudoephedrine |
Increased arterial pressure |
| Rivastigmine |
Possible antagonism of action |
| Rizatriptan |
The MAO inhibitor increases the effect and toxicity of rizatriptan |
| Salbutamol |
Increased arterial pressure |
| Sertraline |
Possible severe adverse reaction with this combination |
| Sibutramine |
Possible serotoninergic syndrome with this combination |
| Sumatriptan |
The MAO inhibitor increases the effect and toxicity of 5-HT agonist |
| Terbutaline |
Increased arterial pressure |
| Tetrabenazine |
CNS stimulation, hypertensive upsurge with this combination |
| Tolazamide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Tolbutamide |
The MAO inhibitor increases the effect of the hypoglycemic agent |
| Tolcapone |
Possible hypertensive crisis with this combination |
| Tramadol |
Increased risk of seizures and serotonin syndrome |
| Trimipramine |
Possibility of severe adverse effects |
| Tryptophanyl-5'amp |
Possible severe adverse reaction with this combination |
| Venlafaxine |
Possible severe adverse reaction with this combination |
| Zolmitriptan |
The MAO inhibitor increases the effect and toxicity of 5-HT agonist |
|
| Food Interactions |
- Avoid St.John's Wort.
- Avoid aged foods (cheese, red wine), pickled foods, cured foods (bacon/ham), chocolate, fava beans, beer, unless approved by your physician.
- Avoid alcohol.
- Avoid excessive quantities of coffee or tea (Caffeine).
- Take without regard to meals.
|
| Pathways |
Not Available
|
| General References |
- Drugs.com

- Wikipedia

- RxList

|
| Organisms Affected |
|
| Phase 1 Metabolizing Enzymes |
- Cytochrome P450 2E1 (CYP2E1)
- Monoamine oxidase type A (MAO-A)
- Monoamine oxidase type B (MAO-B)
|
| Targets |
- Membrane copper amine oxidase
- Amine oxidase [flavin-containing] B
- Amine oxidase [flavin-containing] A
|
|
Drug Target 1
[top]
|
| Target 1 ID |
1483 |
| Target 1 Name |
Membrane copper amine oxidase |
| Target 1 Synonyms |
- EC 1.4.3.6
- HPAO
- SSAO
- Semicarbazide-sensitive amine oxidase
- VAP-1
- Vascular adhesion protein 1
|
| Target 1 Gene Name |
AOC3 |
| Target 1 Protein Sequence |
>Membrane copper amine oxidase
MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQPWTHPGQSQLF
ADLSREELTAVMRFLTQRLGPGLVDAAQARPSDNCVFSVELQLPPKAAALAHLDRGSPPP
AREALAIVFFGRQPQPNVSELVVGPLPHPSYMRDVTVERHGGPLPYHRRPVLFQEYLDID
QMIFNRELPQASGLLHHCCFYKHRGRNLVTMTTAPRGLQSGDRATWFGLYYNISGAGFFL
HHVGLELLVNHKALDPARWTIQKVFYQGRYYDSLAQLEAQFEAGLVNVVLIPDNGTGGSW
SLKSPVPPGPAPPLQFYPQGPRFSVQGSRVASSLWTFSFGLGAFSGPRIFDVRFQGERLV
YEISLQEALAIYGGNSPAAMTTRYVDGGFGMGKYTTPLTRGVDCPYLATYVDWHFLLESQ
APKTIRDAFCVFEQNQGLPLRRHHSDLYSHYFGGLAETVLVVRSMSTLLNYDYVWDTVFH
PSGAIEIRFYATGYISSAFLFGATGKYGNQVSEHTLGTVHTHSAHFKVDLDVAGLENWVW
AEDMVFVPMAVPWSPEHQLQRLQVTRKLLEMEEQAAFLVGSATPRYLYLASNHSNKWGHP
RGYRIQMLSFAGEPLPQNSSMARGFSWERYQLAVTQRKEEEPSSSSVFNQNDPWAPTVDF
SDFINNETIAGKDLVAWVTAGFLHIPHAEDIPNTVTVGNGVGFFLRPYNFFDEDPSFYSA
DSIYFRGDQDAGACEVNPLACLPQAAACAPDLPAFSHGGFSHN
|
| Target 1 Number of Residues |
775 |
| Target 1 Molecular Weight |
84623 |
| Target 1 Theoretical pI |
6.51 |
| Target 1 GO Classification |
|
Function
|
binding
ion binding
cation binding
transition metal ion binding
copper ion binding |
|
Process
|
| Not Available |
|
Component
|
| Not Available |
|
| Target 1 General Function |
Secondary metabolites biosynthesis, transport and catabolism |
| Target 1 Specific Function |
Cell adhesion protein that participates in lymphocyte recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin- independent fashion. Has a monoamine oxidase activity |
| Target 1 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Glycine, serine and threonine metabolism |
SMP00004  |
map00260  |
|
| Target 1 Reactions |
- RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2
|
| Target 1 Pfam Domain Function |
|
| Target 1 Signals |
|
| Target 1 Transmembrane Regions |
|
| Target 1 Essentiality |
Non-Essential |
| Target 1 GenBank ID Protein |
1399032  |
| Target 1 UniProtKB/Swiss-Prot ID |
Q16853  |
| Target 1 UniProtKB/Swiss-Prot Entry Name |
AOC3_HUMAN  |
| Target 1 PDB ID |
1PU4  |
| Target 1 PDB File |
Show |
| Target 1 3D Structure |
|
| Target 1 Cellular Location |
- Membrane
- single-pass type II membrane protein
|
| Target 1 Gene Sequence |
>2292 bp
ATGAACCAGAAGACAATCCTCGTGCTCCTCATTCTGGCCGTCATCACCATCTTTGCCTTG
GTTTGTGTCCTGCTGGTGGGCAGGGGTGGAGATGGGGGTGAACCCAGCCAGCTTCCCCAT
TGCCCCTCTGTATCTCCCAGTGCCCAGCCTTGGACACACCCTGGCCAGAGCCAGCTGTTT
GCAGACCTGAGCCGAGAGGAGCTGACGGCTGTGATGCGCTTTCTGACCCAGCGGCTGGGG
CCAGGGCTGGTGGATGCAGCCCAGGCCCGGCCCTCGGACAACTGTGTCTTCTCAGTGGAG
TTGCAGCTGCCTCCCAAGGCTGCAGCCCTGGCTCACTTGGACAGGGGGAGCCCCCCACCT
GCCCGGGAGGCACTGGCCATCGTCTTCTTTGGCAGGCAACCCCAGCCCAACGTGAGTGAG
CTGGTGGTGGGGCCACTGCCTCACCCCTCCTACATGCGGGACGTGACTGTGGAGCGTCAT
GGAGGCCCCCTGCCCTATCACCGACGCCCCGTGCTGTTCCAAGAGTACCTGGACATAGAC
CAGATGATCTTCAACAGAGAGCTGCCCCAGGCTTCTGGGCTTCTCCACCACTGTTGCTTC
TACAAGCACCGGGGACGGAACCTGGTGACAATGACCACGGCTCCCCGTGGTCTGCAATCA
GGGGACCGGGCCACCTGGTTTGGCCTCTACTACAACATCTCGGGCGCTGGGTTCTTCCTG
CACCACGTGGGCTTGGAGCTGCTAGTGAACCACAAGGCCCTTGACCCTGCCCGCTGGACT
ATCCAGAAGGTGTTCTATCAAGGCCGCTACTACGACAGCCTGGCCCAGCTGGAGGCCCAG
TTTGAGGCCGGCCTGGTGAATGTGGTGCTGATCCCAGACAATGGCACAGGTGGGTCCTGG
TCCCTGAAGTCCCCTGTGCCCCCGGGTCCAGCTCCCCCTCTACAGTTCTATCCCCAAGGC
CCCCGCTTCAGTGTCCAGGGAAGTCGAGTGGCCTCCTCACTGTGGACTTTCTCCTTTGGC
CTCGGAGCATTCAGTGGCCCAAGGATCTTTGACGTTCGCTTCCAAGGAGAAAGACTAGTT
TATGAGATAAGCCTCCAAGAGGCCTTGGCCATCTATGGTGGAAATTCCCCAGCAGCAATG
ACGACCCGCTATGTGGATGGAGGCTTTGGCATGGGCAAGTACACCACGCCCCTGACCCGT
GGGGTGGACTGCCCCTACTTGGCCACCTACGTGGACTGGCACTTCCTTTTGGAGTCCCAG
GCCCCCAAGACAATACGTGATGCCTTTTGTGTGTTTGAACAGAACCAGGGCCTCCCCCTG
CGGCGACACCACTCAGATCTCTACTCGCACTACTTTGGGGGTCTTGCGGAAACGGTGCTG
GTCGTCAGATCTATGTCCACCTTGCTCAACTATGACTATGTGTGGGATACGGTCTTCCAC
CCCAGTGGGGCCATAGAAATACGATTCTATGCCACGGGCTACATCAGCTCGGCATTCCTC
TTTGGTGCTACTGGGAAGTACGGGAACCAAGTGTCAGAGCACACCCTGGGCACGGTCCAC
ACCCACAGCGCCCACTTCAAGGTGGATCTGGATGTAGCAGGACTGGAGAACTGGGTCTGG
GCCGAGGATATGGTCTTTGTCCCCATGGCTGTGCCCTGGAGCCCTGAGCACCAGCTGCAG
AGGCTGCAGGTGACCCGGAAGCTGCTGGAGATGGAGGAGCAGGCCGCCTTCCTCGTGGGA
AGCGCCACCCCTCGCTACCTGTACCTGGCCAGCAACCACAGCAACAAGTGGGGTCACCCC
CGGGGCTACCGCATCCAGATGCTCAGCTTTGCTGGAGAGCCGCTGCCCCAAAACAGCTCC
ATGGCGAGAGGCTTCAGCTGGGAGAGGTACCAGCTGGCTGTGACCCAGCGGAAGGAGGAG
GAGCCCAGTAGCAGCAGCGTTTTCAATCAGAATGACCCTTGGGCCCCCACTGTGGATTTC
AGTGACTTCATCAACAATGAGACCATTGCTGGAAAGGATTTGGTGGCCTGGGTGACAGCT
GGTTTTCTGCATATCCCACATGCAGAGGACATTCCTAACACAGTGACTGTGGGGAACGGC
GTGGGCTTCTTCCTCCGACCCTATAACTTCTTTGACGAAGACCCCTCCTTCTACTCTGCC
GACTCCATCTACTTCCGAGGGGACCAGGATGCTGGGGCCTGCGAGGTCAACCCCCTAGCT
TGCCTGCCCCAGGCTGCTGCCTGTGCCCCCGACCTCCCTGCCTTCTCCCACGGGGGCTTC
TCTCACAACTAG
|
| Target 1 GenBank Gene ID |
|
| Target 1 GeneCard ID |
AOC3  |
| Target 1 GenAtlas ID |
AOC3  |
| Target 1 HGNC ID |
HGNC:550  |
| Target 1 Chromosome Location |
17 |
| Target 1 Locus |
17q21 |
| Target 1 SNPs |
SNPJam Report  |
| Target 1 General References |
- Zhang X, McIntire WS: Cloning and sequencing of a copper-containing, topa quinone-containing monoamine oxidase from human placenta. Gene. 1996 Nov 14;179(2):279-86. [PubMed
]
- Smith DJ, Salmi M, Bono P, Hellman J, Leu T, Jalkanen S: Cloning of vascular adhesion protein 1 reveals a novel multifunctional adhesion molecule. J Exp Med. 1998 Jul 6;188(1):17-27. [PubMed
]
|
| Target 1 Drug References |
- Tipnis UR, Tao M, Boor PJ: Purification and characterization of semicarbazide-sensitive amine oxidase from porcine aorta. Cell Mol Biol (Noisy-le-grand). 1992 Aug-Sep;38(5-6):575-84. [PubMed
]
- Holt A, Baker GB: Metabolism of agmatine (clonidine-displacing substance) by diamine oxidase and the possible implications for studies of imidazoline receptors. Prog Brain Res. 1995;106:187-97. [PubMed
]
- Kumar D, Trent MB, Boor PJ: Allylamine and beta-aminopropionitrile induced aortic medial necrosis: mechanisms of synergism. Toxicology. 1998 Feb 6;125(2-3):107-15. [PubMed
]
|
|
Drug Target 2
[top]
|
| Target 2 ID |
3939 |
| Target 2 Name |
Amine oxidase [flavin-containing] B |
| Target 2 Synonyms |
- EC 1.4.3.4
- MAO-B
- Monoamine oxidase type B
|
| Target 2 Gene Name |
MAOB |
| Target 2 Protein Sequence |
>Amine oxidase [flavin-containing] B
MSNKCDVVVVGGGISGMAAAKLLHDSGLNVVVLEARDRVGGRTYTLRNQKVKYVDLGGSY
VGPTQNRILRLAKELGLETYKVNEVERLIHHVKGKSYPFRGPFPPVWNPITYLDHNNFWR
TMDDMGREIPSDAPWKAPLAEEWDNMTMKELLDKLCWTESAKQLATLFVNLCVTAETHEV
SALWFLWYVKQCGGTTRIISTTNGGQERKFVGGSGQVSERIMDLLGDRVKLERPVIYIDQ
TRENVLVETLNHEMYEAKYVISAIPPTLGMKIHFNPPLPMMRNQMITRVPLGSVIKCIVY
YKEPFWRKKDYCGTMIIDGEEAPVAYTLDDTKPEGNYAAIMGFILAHKARKLARLTKEER
LKKLCELYAKVLGSLEALEPVHYEEKNWCEEQYSGGCYTTYFPPGILTQYGRVLRQPVDR
IYFAGTETATHWSGYMEGAVEAGERAAREILHAMGKIPEDEIWQSEPESVDVPAQPITTT
FLERHLPSVPGLLRLIGLTTIFSATALGFLAHKRGLLVRV
|
| Target 2 Number of Residues |
528 |
| Target 2 Molecular Weight |
58764 |
| Target 2 Theoretical pI |
7.55 |
| Target 2 GO Classification |
|
Function
|
catalytic activity
oxidoreductase activity |
|
Process
|
physiological process
metabolism
cellular metabolism
generation of precursor metabolites and energy
electron transport |
|
Component
|
| Not Available |
|
| Target 2 General Function |
Amino acid transport and metabolism |
| Target 2 Specific Function |
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOB preferentially degrades benzylamine and phenylethylamine |
| Target 2 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Tryptophan metabolism |
|
map00220  |
|
| Target 2 Reactions |
- RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2
|
| Target 2 Pfam Domain Function |
|
| Target 2 Signals |
|
| Target 2 Transmembrane Regions |
|
| Target 2 Essentiality |
Non-Essential |
| Target 2 GenBank ID Protein |
398415  |
| Target 2 UniProtKB/Swiss-Prot ID |
P27338  |
| Target 2 UniProtKB/Swiss-Prot Entry Name |
AOFB_HUMAN  |
| Target 2 PDB ID |
2BK3  |
| Target 2 PDB File |
Show |
| Target 2 3D Structure |
|
| Target 2 Cellular Location |
|
| Target 2 Gene Sequence |
>1560 bp
ATGAGCAACAAATGCGACGTGGTCGTGGTGGGGGGCGGCATCTCAGGTATGGCAGCAGCC
AAACTTCTGCATGACTCTGGACTGAATGTGGTTGTTCTGGAAGCCCGGGACCGTGTGGGA
GGCAGGACTTACACTCTTAGGAACCAAAAGGTTAAATATGTGGACCTTGGAGGATCCTAT
GTTGGACCAACCCAGAATCGTATCTTGAGATTAGCCAAGGAGCTAGGATTGGAGACCTAC
AAAGTGAATGAGGTTGAGCGTCTGATCCACCATGTAAAGGGCAAATCATACCCCTTCAGG
GGGCCATTCCCACCTGTATGGAATCCAATTACCTACTTAGATCATAACAACTTTTGGAGG
ACAATGGATGACATGGGGCGAGAGATTCCGAGTGATGCCCCATGGAAGGCTCCCCTTGCA
GAAGAGTGGGACAACATGACAATGAAGGAGCTACTGGACAAGCTCTGCTGGACTGAATCT
GCAAAGCAGCTTGCCACTCTCTTTGTGAACCTGTGTGTCACTGCAGAGACCCATGAGGTC
TCTGCTCTCTGGTTCCTGTGGTATGTGAAGCAGTGTGGAGGCACAACAAGAATCATCTCG
ACAACAAATGGAGGACAGGAGAGGAAATTTGTGGGCGGATCTGGTCAAGTGAGTGAGCGG
ATAATGGACCTCCTTGGAGACCGAGTGAAGCTGGAGAGGCCTGTGATCTACATTGACCAG
ACAAGAGAAAATGTCCTTGTGGAGACCCTAAACCATGAGATGTATGAGGCTAAATATGTG
ATTAGTGCTATTCCTCCTACTCTGGGCATGAAGATTCACTTCAATCCCCCTCTGCCAATG
ATGAGAAACCAGATGATCACTCGTGTGCCTTTGGGTTCAGTCATCAAGTGTATAGTTTAT
TATAAAGAGCCTTTCTGGAGGAAAAAGGATTACTGTGGAACCATGATTATTGATGGAGAA
GAAGCTCCAGTTGCCTACACGTTGGATGATACCAAACCTGAAGGCAACTATGCTGCCATA
ATGGGATTTATCCTGGCCCACAAAGCCAGAAAACTGGCACGTCTTACCAAAGAGGAAAGG
TTGAAGAAACTTTGTGAACTCTATGCCAAGGTTCTGGGTTCCCTAGAAGCTCTGGAGCCA
GTGCATTATGAAGAAAAGAACTGGTGTGAGGAGCAGTACTCTGGGGGCTGCTACACAACT
TATTTCCCCCCTGGGATCCTGACTCAATATGGAAGGGTTCTACGCCAGCCAGTGGACAGG
ATTTACTTTGCAGGCACCGAGACTGCCACACACTGGAGCGGCTACATGGAGGGGGCTGTA
GAGGCCGGGGAGAGAGCAGCCCGAGAGATCCTGCATGCCATGGGGAAGATTCCAGAGGAT
GAAATCTGGCAGTCAGAACCAGAGTCTGTGGATGTCCCTGCACAGCCCATCACCACCACC
TTTTTGGAGAGACATTTGCCCTCCGTGCCAGGCCTGCTCAGGCTGATTGGATTGACCACC
ATCTTTTCAGCAACGGCTCTTGGCTTCCTGGCCCACAAAAGGGGGCTACTTGTGAGAGTC
|
| Target 2 GenBank Gene ID |
|
| Target 2 GeneCard ID |
MAOB  |
| Target 2 GenAtlas ID |
MAOB  |
| Target 2 HGNC ID |
HGNC:6834  |
| Target 2 Chromosome Location |
X |
| Target 2 Locus |
Xp11.23 |
| Target 2 SNPs |
SNPJam Report  |
| Target 2 General References |
- Newton-Vinson P, Hubalek F, Edmondson DE: High-level expression of human liver monoamine oxidase B in Pichia pastoris. Protein Expr Purif. 2000 Nov;20(2):334-45. [PubMed
]
- Binda C, Newton-Vinson P, Hubalek F, Edmondson DE, Mattevi A: Structure of human monoamine oxidase B, a drug target for the treatment of neurological disorders. Nat Struct Biol. 2002 Jan;9(1):22-6. [PubMed
]
- Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46. [PubMed
]
- Grimsby J, Chen K, Wang LJ, Lan NC, Shih JC: Human monoamine oxidase A and B genes exhibit identical exon-intron organization. Proc Natl Acad Sci U S A. 1991 May 1;88(9):3637-41. [PubMed
]
- Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8. [PubMed
]
- Chen K, Wu HF, Shih JC: The deduced amino acid sequences of human platelet and frontal cortex monoamine oxidase B are identical. J Neurochem. 1993 Jul;61(1):187-90. [PubMed
]
|
| Target 2 Drug References |
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed
]
|
|
Drug Target 3
[top]
|
| Target 3 ID |
3941 |
| Target 3 Name |
Amine oxidase [flavin-containing] A |
| Target 3 Synonyms |
- EC 1.4.3.4
- MAO-A
- Monoamine oxidase type A
|
| Target 3 Gene Name |
MAOA |
| Target 3 Protein Sequence |
>Amine oxidase [flavin-containing] A
MENQEKASIAGHMFDVVVIGGGISGLSAAKLLTEYGVSVLVLEARDRVGGRTYTIRNEHV
DYVDVGGAYVGPTQNRILRLSKELGIETYKVNVSERLVQYVKGKTYPFRGAFPPVWNPIA
YLDYNNLWRTIDNMGKEIPTDAPWEAQHADKWDKMTMKELIDKICWTKTARRFAYLFVNI
NVTSEPHEVSALWFLWYVKQCGGTTRIFSVTNGGQERKFVGGSGQVSERIMDLLGDQVKL
NHPVTHVDQSSDNIIIETLNHEHYECKYVINAIPPTLTAKIHFRPELPAERNQLIQRLPM
GAVIKCMMYYKEAFWKKKDYCGCMIIEDEDAPISITLDDTKPDGSLPAIMGFILARKADR
LAKLHKEIRKKKICELYAKVLGSQEALHPVHYEEKNWCEEQYSGGCYTAYFPPGIMTQYG
RVIRQPVGRIFFAGTETATKWSGYMEGAVEAGERAAREVLNGLGKVTEKDIWVQEPESKD
VPAVEITHTFWERNLPSVSGLLKIIGFSTSVTALGFVLYKYKLLPRS
|
| Target 3 Number of Residues |
535 |
| Target 3 Molecular Weight |
59682 |
| Target 3 Theoretical pI |
7.96 |
| Target 3 GO Classification |
|
Function
|
catalytic activity
oxidoreductase activity |
|
Process
|
physiological process
metabolism
cellular metabolism
generation of precursor metabolites and energy
electron transport |
|
Component
|
| Not Available |
|
| Target 3 General Function |
Amino acid transport and metabolism |
| Target 3 Specific Function |
Catalyzes the oxidative deamination of biogenic and xenobiotic amines and has important functions in the metabolism of neuroactive and vasoactive amines in the central nervous system and peripheral tissues. MAOA preferentially oxidizes biogenic amines such as 5-hydroxytryptamine (5-HT), norepinephrine and epinephrine |
| Target 3 Pathways |
| Name |
SMPDB Link |
KEGG Link |
| Tryptophan metabolism |
|
map00220  |
|
| Target 3 Reactions |
- RCH2NH2 + H2O + O2 = RCHO + NH3 + H2O2
|
| Target 3 Pfam Domain Function |
|
| Target 3 Signals |
|
| Target 3 Transmembrane Regions |
|
| Target 3 Essentiality |
Non-Essential |
| Target 3 GenBank ID Protein |
187353  |
| Target 3 UniProtKB/Swiss-Prot ID |
P21397  |
| Target 3 UniProtKB/Swiss-Prot Entry Name |
AOFA_HUMAN  |
| Target 3 PDB ID |
1O5W  |
| Target 3 PDB File |
Show |
| Target 3 3D Structure |
|
| Target 3 Cellular Location |
|
| Target 3 Gene Sequence |
>1584 bp
ATGGAGAATCAAGAGAAGGCGAGTATCGCGGGCCACATGTTCGACGTAGTCGTGATCGGA
GGTGGCATTTCAGGACTATCTGCTGCCAAACTCTTGACTGAATATGGCGTTAGTGTTTTG
GTTTTAGAAGCTCGGGACAGGGTTGGAGGAAGAACATATACTATAAGGAATGAGCATGTT
GATTACGTAGATGTTGGTGGAGCTTATGTGGGACCAACCCAAAACAGAATCTTACGCTTG
TCTAAGGAGCTGGGCATAGAGACTTACAAAGTGAATGTCAGTGAGCGTCTCGTTCAATAT
GTCAAGGGGAAAACATATCCATTTCGGGGCGCCTTTCCACCAGTATGGAATCCCATTGCA
TATTTGGATTACAATAATCTGTGGAGGACAATAGATAACATGGGGAAGGAGATTCCAACT
GATGCACCCTGGGAGGCTCAACATGCTGACAAATGGGACAAAATGACCATGAAAGAGCTC
ATTGACAAAATCTGCTGGACAAAGACTGCTAGGCGGTTTGCTTATCTTTTTGTGAATATC
AATGTGACCTCTGAGCCTCACGAAGTGTCTGCCCTGTGGTTCTTGTGGTATGTGAAGCAG
TGCGGGGGCACCACTCGGATATTCTCTGTCACCAATGGTGGCCAGGAACGGAAGTTTGTA
GGTGGATCTGGTCAAGTGAGCGAACGGATAATGGACCTCCTCGGAGACCAAGTGAAGCTG
AACCATCCTGTCACTCACGTTGACCAGTCAAGTGACAACATCATCATAGAGACGCTGAAC
CATGAACATTATGAGTGCAAATACGTAATTAATGCGATCCCTCCGACCTTGACTGCCAAG
ATTCACTTCAGACCAGAGCTTCCAGCAGAGAGAAACCAGTTAATTCAGCGGCTTCCAATG
GGAGCTGTCATTAAGTGCATGATGTATTACAAGGAGGCCTTCTGGAAGAAGAAGGATTAC
TGTGGCTGCATGATCATTGAAGATGAAGATGCTCCAATTTCAATAACCTTGGATGACACC
AAGCCTGATGGGTCACTGCCTGCCATCATGGGCTTCATTCTTGCCCGGAAAGCTGATCGA
CTTGCTAAGCTACATAAGGAAATAAGGAAGAAGAAAATCTGTGAGCTCTATGCCAAAGTG
CTGGGATCCCAAGAAGCTTTACATCCAGTGCATTATGAAGAGAAGAACTGGTGTGAGGAG
CAGTACTCTGGGGGCTGCTACACGGCCTACTTCCCTCCTGGGATCATGACTCAATATGGA
AGGGTGATTCGTCAACCCGTGGGCAGGATTTTCTTTGCGGGCACAGAGACTGCCACAAAG
TGGAGCGGCTACATGGAAGGGGCAGTTGAGGCTGGAGAACGAGCAGCTAGGGAGGTCTTA
AATGGTCTCGGGAAGGTGACCGAGAAAGATATCTGGGTACAAGAACCTGAATCAAAGGAC
GTTCCAGCGGTAGAAATCACCCACACCTTCTGGGAAAGGAACCTGCCCTCTGTTTCTGGC
CTGCTGAAGATCATTGGATTTTCCACATCAGTAACTGCCCTGGGGTTTGTGCTGTACAAA
TACAAGCTCCTGCCACGGTCTTGA
|
| Target 3 GenBank Gene ID |
|
| Target 3 GeneCard ID |
MAOA  |
| Target 3 GenAtlas ID |
MAOA  |
| Target 3 HGNC ID |
HGNC:6833  |
| Target 3 Chromosome Location |
X |
| Target 3 Locus |
Xp11.3 |
| Target 3 SNPs |
SNPJam Report  |
| Target 3 General References |
- Li M, Hubalek F, Newton-Vinson P, Edmondson DE: High-level expression of human liver monoamine oxidase A in Pichia pastoris: comparison with the enzyme expressed in Saccharomyces cerevisiae. Protein Expr Purif. 2002 Feb;24(1):152-62. [PubMed
]
- Zhu QS, Grimsby J, Chen K, Shih JC: Promoter organization and activity of human monoamine oxidase (MAO) A and B genes. J Neurosci. 1992 Nov;12(11):4437-46. [PubMed
]
- Weyler W: Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit. Biochem J. 1989 Jun 15;260(3):725-9. [PubMed
]
- Chen SA, Weyler W: Partial amino acid sequence analysis of human placenta monoamine oxidase A and bovine liver monoamine oxidase B. Biochem Biophys Res Commun. 1988 Oct 14;156(1):445-50. [PubMed
]
- Bach AW, Lan NC, Johnson DL, Abell CW, Bembenek ME, Kwan SW, Seeburg PH, Shih JC: cDNA cloning of human liver monoamine oxidase A and B: molecular basis of differences in enzymatic properties. Proc Natl Acad Sci U S A. 1988 Jul;85(13):4934-8. [PubMed
]
- Hsu YP, Weyler W, Chen S, Sims KB, Rinehart WB, Utterback MC, Powell JF, Breakefield XO: Structural features of human monoamine oxidase A elucidated from cDNA and peptide sequences. J Neurochem. 1988 Oct;51(4):1321-4. [PubMed
]
- Denney RM, Sharma A, Dave SK, Waguespack A: A new look at the promoter of the human monoamine oxidase A gene: mapping transcription initiation sites and capacity to drive luciferase expression. J Neurochem. 1994 Sep;63(3):843-56. [PubMed
]
- Denney RM: The promoter of the human monoamine oxidase A gene. Prog Brain Res. 1995;106:57-66. [PubMed
]
|
| Target 3 Drug References |
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed
]
|